C12N 2770/20043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2770/20043 (Viral genome or elements thereof as genetic vector) appears on 18 US grants and 54 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 54
- Assignees
- 50
- Inventors
- 163
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 2 | 1 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 3 |
| 2007 | 1 | 2 |
| 2008 | 2 | 0 |
| 2009 | 2 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 17 |
| 2024 | 0 | 8 |
| 2025 | 2 | 5 |
| 2026 | 4 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified gene vaccines against avian coronaviruses and methods of using the same21 Jul 2026US 12,685,766 B2Wisconsin Alumni Research Foundation
- Single-chain coronavirus viral membrane protein complexes24 Mar 2026US 12,582,710 B2University of Houston System
- Methods for control of an infective disease with a vaccine24 Mar 2026US 12,583,890 B2Russellville Cardiology Consultants, P.A.
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Coronavirus vaccine28 Jan 2025US 12,208,136 B2BioNTech SE
- Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof6 Aug 2026US 2026/0226462 A1Elixirgen Therapeutics, Inc.
- Sars coronavirus 2 recombinant vectors expressing reporter genes, derived from gh clade sars coronavirus 2 of korean isolate, and the production method therefor12 Mar 2026US 2026/0071190 A1RpexBio, Inc.
- Self-replicating rna vaccines and methods of use8 Jan 2026US 2026/0007738 A1Immorna (Hangzhou) Biotechnology Co., Ltd.
- Therapeutic interfering particles for corona virus6 Nov 2025US 2025/0339508 A1The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad
- One-to-stop attenuated sars-cov-2 virus25 Sep 2025US 2025/0295757 A1Institut FüR Virologie Und Immunologie (Ivi)
Most cited
By later US patents
- Directional assembly of large viral genomes and chromosomes20US 6,593,111 B2The University of North Carolina at Chapel Hill · 2003
- Induce and enhance immune responses using recombinant replicon systems12US 11,083,786 B2Janssen Pharmaceuticals, Inc. · 2021
- Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines6US 7,041,300 B1Cyanamid Iberica, S.A. · 2006
- Canine coronavirus S gene and uses therefor5US 6,057,436 APfizer Inc. · 2000
- Canine coronavirus S gene and uses therefor5US 6,372,224 B1Pfizer Inc. · 2002